Literature DB >> 34851479

Investigation of VHL gene associated with miR-223 in clear cell renal cell carcinoma.

Ufuk Unal1, Gulsah Cecener2, Havva Tezcan Unlu1, Berna Aytac Vuruskan3, Ecem Efendi Erdem1, Unal Egeli1, Hulya Ozturk Nazlioglu3, Onur Kaygisiz4, Berrin Tunca1, Hakan Vuruskan4.   

Abstract

BACKGROUND: Clear cell type renal cell carcinoma (ccRCC) is the most common renal cell carcinoma (RCC). In this study, we examined the expressions of VHL and miR-223 in ccRCC patients׳ tissues to investigate the possible role in the development of ccRCC. METHODS AND
RESULTS: This study collected five expression profiles (GSE36139, GSE3, GSE73731, GSE40435, and GSE26032) from Gene Omnibus Data. Expressions of VHL and miR-223 in paraffinized tumor and normal tissues of 100 Turkish patients' ccRCC tissues were determined by bioinformatic data mining and real-time quantitative polymerase chain reaction (qRT-PCR). The VHL gene was subjected to mutational analysis by DNA sequencing, and pVHL was analyzed using western blotting. Our study's t-test and Pearson correlation analysis showed that VHL gene expression in tumoral tissues with a - 0.39-fold decrease was not significantly lower than normal tissues (p = 0.441), and a 0.97-fold increase miR-223 (p = 0.045) was determined by real-time PCR. Also, as a result of DNA sequence analysis performed in the VHL gene, it was found that 26% of the patients have mutations. The mutations for (VHL):c.60C>A (p.Val20=) and (VHL):c.467delA (p.Tyr156Leu) was detected for the first time in Turkish patients.
CONCLUSIONS: The present study demonstrated that the differences in the expression levels of miR-223 have the potential to be biomarkers to determine the poor prognosis in ccRCC.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  In silico data; VHL; ccRCC; miR-223

Mesh:

Substances:

Year:  2021        PMID: 34851479     DOI: 10.1007/s11033-021-07025-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  16 in total

1.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

2.  Identification of a three-miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma.

Authors:  Yongwen Luo; Liang Chen; Gang Wang; Yu Xiao; Lingao Ju; Xinghuan Wang
Journal:  J Cell Biochem       Date:  2019-04-07       Impact factor: 4.429

Review 3.  Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer.

Authors:  Maxwell Shulman; Rachel Shi; Qing Zhang
Journal:  J Genet Genomics       Date:  2021-07-09       Impact factor: 5.723

Review 4.  The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.

Authors:  Peter E Clark
Journal:  Kidney Int       Date:  2009-08-05       Impact factor: 10.612

5.  Single-Cell Transcriptome Analysis Reveals Intratumoral Heterogeneity in ccRCC, which Results in Different Clinical Outcomes.

Authors:  Junyi Hu; Zhaohui Chen; Lin Bao; Lijie Zhou; Yaxin Hou; Lilong Liu; Ming Xiong; Yuhan Zhang; Bin Wang; Zhen Tao; Ke Chen
Journal:  Mol Ther       Date:  2020-04-29       Impact factor: 11.454

Review 6.  VHL, the story of a tumour suppressor gene.

Authors:  Lucy Gossage; Tim Eisen; Eamonn R Maher
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 7.  A Review of Von Hippel-Lindau Syndrome.

Authors:  Neha Varshney; Amanuel A Kebede; Harry Owusu-Dapaah; Jason Lather; Manu Kaushik; Jasneet S Bhullar
Journal:  J Kidney Cancer VHL       Date:  2017-08-02

8.  Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3/VEGFA signalling pathway.

Authors:  Fuqing Hu; Xuling Sun; Geng Li; Qi Wu; Yaqi Chen; Xi Yang; Xuelai Luo; Junbo Hu; Guihua Wang
Journal:  Cell Death Dis       Date:  2018-12-18       Impact factor: 8.469

Review 9.  Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.

Authors:  Marco Gerlinger; James W Catto; Torben F Orntoft; Francisco X Real; Ellen C Zwarthoff; Charles Swanton
Journal:  Eur Urol       Date:  2014-05-02       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.